Molecular defects in mastocytosis: KIT and beyond KIT.

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 239-262

  Bibi, Siham ^a   Langenfeld, Florent ^a   Jeanningros, Sylvie ^a   Brenet, Fabienne ^b,c,d   Soucie, Erinn ^b,c,d   Hermine, Olivier ^e   Damaj, Gandhi ^e,f   Dubreuil, Patrice ^b,c,d,e   Arock, Michel ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CNRS   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

ASXL1; KIT; Mutation; Signaling; Spliceosome; Systemic mastocytosis; Targeted therapy; TET2

Indexed keywords

DASATINIB; IMATINIB; MASITINIB; MIDOSTAURIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRYPTASE; ASXL1 PROTEIN, HUMAN; DNA BINDING PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

ASXL1 GENE; BONE MARROW BIOPSY; CARCINOGENESIS; CBL GENE; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DNMT3A GENE; DRUG TARGETING; ENZYME SPECIFICITY; ETV6 GENE; EZH2 GENE; FAMILIAL DISEASE; GAIN OF FUNCTION MUTATION; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; LOSS OF FUNCTION MUTATION; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOMA; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE C KIT; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RUNX1 GENE; SARCOMA; SETBP1 GENE; SF3B1 GENE; SIGNAL TRANSDUCTION; SPLICEOSOME; SYSTEMIC MASTOCYTOSIS; TET2 GENE; BONE MARROW; CELL PROLIFERATION; DRUG EFFECTS; EXON; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC NEOPLASMS; MASTOCYTOSIS; METABOLISM; MUTATION; PATHOLOGY;

BONE MARROW; CELL PROLIFERATION; DNA-BINDING PROTEINS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MAST CELLS; MASTOCYTOSIS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SPLICEOSOMES; STEM CELL FACTOR;

EID: 84898682986     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.009     Document Type: Review

References (118)

1. Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94:2333-2342.
2. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
3. Li L., Meng X.W., Krilis S.A. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand. JImmunol 1996, 156:4839-4844.
4. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Immunol Today 1994, 15:111-114.
5. Valent P. Systemic mastocytosis. Cancer Treat Res 2008, 142:399-419.
6. Arock M., Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010, 3:497-516.
7. Feger F., Ribadeau Dumas A., Leriche L., et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002, 127:110-114.
8. Traina F., Visconte V., Jankowska A.M., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012, 7:e43090.
9. Soucie E., Hanssens K., Mercher T., et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012, 120:4846-4849.
10. Schwaab J., Schnittger S., Sotlar K., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013, 122:2460-2466.
11. Morii E. Development of mast cells: analysis with mutant mice. Int J Hematol 2007, 86:22-26.
12. Piao X., Bernstein A. Apoint mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996, 87:3117-3123.
13. Costa J.J., Demetri G.D., Harrist T.J., et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation invivo. JExp Med 1996, 183:2681-2686.
14. Anderson D.M., Williams D.E., Tushinski R., et al. Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24. Cell Growth Differ 1991, 2:373-378.
15. Ashman L.K. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999, 31:1037-1051.
16. Giebel L.B., Strunk K.M., Holmes S.A., et al. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene 1992, 7:2207-2217.
17. Chabot B., Stephenson D.A., Chapman V.M., et al. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988, 335:88-89.
18. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 338:1307-1315.
19. Roskoski R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 337:1-13.
20. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
21. Chan P.M., Ilangumaran S., La Rose J., et al. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 2003, 23:3067-3078.
22. Laine E., Chauvot de Beauchene I., Perahia D., et al. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol 2011, 7:e1002068.
23. Kim M.S., Radinger M., Gilfillan A.M. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 2008, 29:493-501.
24. Vadlakonda L., Dash A., Pasupuleti M., et al. The paradox of Akt-mTOR interactions. Front Oncol 2013, 3:165.
25. Morales J.K., Falanga Y.T., Depcrynski A., et al. Mast cell homeostasis and the JAK-STAT pathway. Genes Immun 2010, 11:599-608.
26. Timokhina I., Kissel H., Stella G., et al. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J 1998, 17:6250-6262.
27. O'Laughlin-Bunner B., Radosevic N., Taylor M.L., et al. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 2001, 98:343-350.
28. Lennartsson J., Blume-Jensen P., Hermanson M., et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 1999, 18:5546-5553.
29. Nishida K., Wang L., Morii E., et al. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. Blood 2002, 99:1866-1869.
30. Samayawardhena L.A., Hu J., Stein P.L., et al. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell Signal 2006, 18:1447-1454.
31. Trieselmann N.Z., Soboloff J., Berger S.A. Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 2003, 60:759-766.
32. Ryan R.J., Akin C., Castells M., et al. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2013, 26:533-543.
33. Briley L.D., Phillips C.M. Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila) 2008, 47:757-761.
34. Pardanani A. Systemic mastocytosis: disease overview, pathogenesis, and treatment. Hematol Oncol Clin North Am 2012, 26:1117-1128.
35. Valent P., Aberer E., Beham-Schmid C., et al. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am J Blood Res 2013, 3:174-180.
36. Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations inmastocytosis: a study of 83 patients. JAllergy Clin Immunol 2013, 132:866-873.e1-3.
37. Stoecker M.M., Wang E. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 2012, 136:832-838.
38. Valent P., Horny H.-P., Li C.Y., et al. Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues 2001, 291-302. IARC Press, Lyon (France). E.S. Jaffe, N.L. Harris, H. Stein (Eds.).
39. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
40. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
41. Valent P., Akin C., Sperr W.R., et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46:35-48.
42. Gleixner K.V., Mayerhofer M., Cerny-Reiterer S., et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011, 118:1885-1898.
43. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
44. Jordan J.H., Fritsche-Polanz R., Sperr W.R., et al. Acase of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res 2001, 25:627-634.
45. Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013, 3:159-172.
46. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. JClin Invest 1993, 92:1736-1744.
47. Tsujimura T., Furitsu T., Morimoto M., et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994, 83:2619-2626.
48. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312-314.
49. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96:1609-1614.
50. Zappulla J.P., Dubreuil P., Desbois S., et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. JExp Med 2005, 202:1635-1641.
51. Buttner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. JInvest Dermatol 1998, 111:1227-1231.
52. Yanagihori H., Oyama N., Nakamura K., et al. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. JMol Diagn 2005, 7:252-257.
53. Verzijl A., Heide R., Oranje A.P., et al. C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology 2007, 214:15-20.
54. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. JInvest Dermatol 2010, 130:804-815.
55. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
56. Kristensen T., Vestergaard H., Moller M.B. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. JMol Diagn 2011, 13:180-188.
57. Kristensen T., Broesby-Olsen S., Vestergaard H., et al. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012, 89:42-46.
58. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. JAllergy Clin Immunol 2010, 125:719-726. 726.e1-4.
59. Gotlib J., Pardanani A., Akin C., et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013, 121:2393-2401.
60. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004, 28:249-257.
61. Georgin-Lavialle S., Lhermitte L., Dubreuil P., et al. Mast cell leukemia. Blood 2013, 121:1285-1295.
62. Pignon J.M., Giraudier S., Duquesnoy P., et al. Anew c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997, 96:374-376.
63. Nakagomi N., Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007, 87:365-371.
64. Sperr W.R., Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 2012, 5:261-274.
65. Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35:1143-1152.
66. Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010, 116:5812-5817.
67. Sotlar K., Fridrich C., Mall A., et al. Detection of c-kit point mutation Asp-816 -> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26:979-984.
68. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.
69. Sotlar K., Colak S., Bache A., et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). JPathol 2010, 220:586-595.
70. Georgin-Lavialle S., Aguilar C., Guieze R., et al. Mast cell sarcoma: a rare and aggressive entity-report of two cases and review of the literature. JClin Oncol 2013, 31:e90-e97.
71. Zhang L.Y., Smith M.L., Schultheis B., et al. Anovel K509I mutation of KIT identified in familial mastocytosis-invitro and invivo responsiveness to imatinib therapy. Leuk Res 2006, 30:373-378.
72. Wasag B., Niedoszytko M., Piskorz A., et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011, 39:859-865.e2.
73. Hoffmann K.M., Moser A., Lohse P., et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 2008, 112:1655-1657.
74. Yang Y., Letard S., Borge L., et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010, 116:1114-1123.
75. Kim S.Y., Kang J.J., Lee H.H., et al. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816. Biochem Biophys Res Commun 2011, 410:224-228.
76. Bougherara H., Georgin-Lavialle S., Damaj G., et al. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications. Clin Lymphoma Myeloma Leuk 2013, 13:62-69.
77. Xiang Z., Kreisel F., Cain J., et al. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 2007, 27:267-282.
78. Choudhary C., Olsen J.V., Brandts C., et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009, 36:326-339.
79. Taylor M.L., Dastych J., Sehgal D., et al. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis. Blood 2001, 98:1195-1199.
80. Chian R., Young S., Danilkovitch-Miagkova A., et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001, 98:1365-1373.
81. Sun J., Pedersen M., Ronnstrand L. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. JBiol Chem 2009, 284:11039-11047.
82. Voisset E., Lopez S., Dubreuil P., et al. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007, 110:2593-2599.
83. Smrz D., Kim M.S., Zhang S., et al. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 2011, 118:6803-6813.
84. Harir N., Boudot C., Friedbichler K., et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008, 112:2463-2473.
85. Gabillot-Carre M., Lepelletier Y., Humbert M., et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006, 108:1065-1072.
86. Baumgartner C., Cerny-Reiterer S., Sonneck K., et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol 2009, 175:2416-2429.
87. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006, 26:575-592.
88. Lindauer M., Hochhaus A. Dasatinib. Recent Results Cancer Res 2010, 184:83-102.
89. Aichberger K.J., Sperr W.R., Gleixner K.V., et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008, 38:869-873.
90. Gani O.A., Engh R.A. Protein kinase inhibition of clinically important staurosporine analogues. Nat Prod Rep 2010, 27:489-498.
91. Gleixner K.V., Peter B., Blatt K., et al. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica 2013, 98(9):1450-1457.
92. Frost M.J., Ferrao P.T., Hughes T.P., et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002, 1:1115-1124.
93. Ashman L.K., Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 2013, 22:103-115.
94. Akin C., Fumo G., Yavuz A.S., et al. Anovel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222-3225.
95. Mital A., Piskorz A., Lewandowski K., et al. Acase of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011, 86:531-535.
96. Alvarez-Twose I., Gonzalez P., Morgado J.M., et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. JClin Oncol 2012, 30:e126-e129.
97. Georgin-Lavialle S., Lhermitte L., Suarez F., et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012, 89:47-52.
98. Tan L., Shi Y.G. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012, 139:1895-1902.
99. Solary E., Bernard O.A., Tefferi A., et al. Ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2013, [Epub ahead of print].
100. Li Z., Cai X., Cai C.L., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
101. Holmfeldt L., Mullighan C.G. The role of TET2 in hematologic neoplasms. Cancer Cell 2011, 20:1-2.
102. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
103. Damaj G., Joris M., Chandesris O., et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014, 1:e85362.
104. Visconte V., Makishima H., Maciejewski J.P., et al. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012, 26:2447-2454.
105. Hanssens K., Brenet F., Agopian J., et al. SRSF2-P95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 2014, [Epub ahead of print].
106. Cho Y.S., Kim E.J., Park U.H., et al. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. JBiol Chem 2006, 281:17588-17598.
107. Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer 2013, 109:299-306.
108. Fisher C.L., Pineault N., Brookes C., et al. Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010, 115:38-46.
109. Delhommeau F., Jeziorowska D., Marzac C., et al. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010, 91:165-173.
110. Abdel-Wahab O., Tefferi A., Levine R.L. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012, 26:1053-1064.
111. Prior I.A., Lewis P.D., Mattos C. Acomprehensive survey of Ras mutations in cancer. Cancer Res 2012, 72:2457-2467.
112. Moroni C., Diamantis I.D., Wodnar-Filipowicz A., et al. Multistage mastocytoma model characterized by autocrine IL-3 production. Haematol Blood Transfus 1989, 32:407-410.
113. Wiesner S.M., Jones J.M., Hasz D.E., et al. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood 2005, 106:1054-1062.
114. Parikh C., Subrahmanyam R., Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006, 108:2349-2357.
115. Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
116. Makishima H., Yoshida K., Nguyen N., et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013, 45:942-946.
117. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004, 23:4284-4296.
118. Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108:286-291.